{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AMN",
  "name": "AMN Healthcare Services",
  "url": "https://orbyd.app/dossiers/AMN/",
  "json_url": "https://orbyd.app/dossiers/AMN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Healthcare-staffing cyclical recovery, real but MATURING and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading price, but the broad Street stays Hold ~$25-30 and the binary 2026-08-06 Q2 print — guide already below consensus — is the swing. Paying up into it is an extended entry.",
  "invalidation_trigger": "A weekly close below $28 breaks the July higher-low base and the rising trend carrying the recovery leg; a close beneath the $26 May breakout shelf resets it to a failed-recovery value trap. Secondary: the 2026-08-06 print guiding Q3 revenue under the ~$630M run-rate, or Jefferies temp-nurse demand negative 3+ straight weeks.",
  "catalyst_date": "2026-08-06",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-07-02",
  "invalidation_fired": false,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Last confirmed tape ~$32.4 (2026-06-18); 52-wk high $32.52 (week of 2026-06-15); +105% off $15.77 YTD low. Tape quiet since - no new analyst actions or catalyst through early July, consistent with the MATURING / no-acceleration frame.",
    "Q2 2026 print CONFIRMED 2026-08-06 after close (~4:15pm ET release, 5:00pm ET call) — binary, do not probe into it. Q2 guide: revenue $620-635M (below $634.9M consensus), gross margin 28-28.5%, adj EBITDA margin 6.7-7.2%.",
    "Truist raised PT to $40 from $26, maintained Buy, 2026-07-22 — new Street high, far above the ~$25-30 Hold consensus. Watch for a follow-on upgrade cluster as the re-acceleration signal; a lone outlier is not a cluster.",
    "Current read: ~$32.89 (2026-07-24), 52-wk range $14.87-$36.27, mkt cap ~$1.28B, no trailing P/E (GAAP loss, TTM net income -$32.44M / EPS -$0.84), forward P/E ~39x.",
    "Mis-themed as managed care; true driver is hospital labor budgets / travel-nurse bill rates. Jefferies weekly temp-nursing demand series is the main high-frequency sector read now that CCRN is going private.",
    "CCRN (Cross Country Healthcare) taken private by Knox Lane at $13.25/sh (~$437M, ~31% premium), close ~Q3 2026 — removes the cleanest listed peer comp.",
    "Jaide Health acquired 2026-06-09 by AMN Language Services — AI-enabled medical interpretation, higher-margin/recurring mix-shift onto a cyclical staffing base.",
    "DATA FLAG: aggregators garble AMN figures. Historical Truist $70-88 and JMP $34-47 marks are OLD; Benzinga 'Q1 Sales $1.378B' and StockStory '$3.42B' are feed errors. Anchor on ~$650-700M quarterly run-rate and the Q2 guide $620-635M."
  ],
  "body_markdown": "## Current Thesis\nAMN is the largest US healthcare-staffing platform (travel nurse, locum tenens, allied health, language services), and the tape keeps confirming the cyclical-recovery break that buried the 2025 dead-trough frame. Last near ~$32.89 (2026-07-24), the stock sits about 9% under a fresh 52-week high of $36.27 and roughly +120% off the $14.87 low. The refresh datapoint is sell-side: Truist raised its target to a Street-high $40 from $26 while maintaining Buy on 2026-07-22 — the first target that leads price rather than lags it, and the closest thing yet to the upgrade cluster the earlier tape lacked. What has not changed is the tension the higher price created: the broad Street stays Hold with consensus clustered ~$25–30, one outlier upgrade is not a cluster, and the Q2 revenue guide of $620–635M sits below the $634.9M consensus. The binary is now dated and close — the Q2 2026 print lands 2026-08-06 after the close, 11 days out. A fresh buyer at the highs pays full price into a print whose own guide already undercuts consensus. The theme reads MATURING, not clean-accelerating: the demand inflection is real, but the entry into overhead target supply ahead of a binary is late-stage, and the clean zone was $16–20 back in Q1.\n\n## Bull Case\n- Truist raised its target to $40 from $26, maintaining Buy on 2026-07-22 — a new Street high well above the ~$25–30 consensus, and the first mark that sits above the current ~$32.89 price; a second and third target following it would form the upgrade cluster the prior leg never had.\n- Demand inflection confirmed across the complex: Jefferies temp-nursing demand +3.6% week-over-week (early June 2026) alongside CCRN Travel Nurse & Allied revenue +7% sequentially (Q1, 2026-05-07) — concrete evidence hospital labor budgets are re-expanding after two years of bill-rate deflation.\n- Private capital marked the bottom: Knox Lane is taking CCRN private at $13.25/share (~$437M, ~31% premium to the 2026-05-06 close), targeted to close ~Q3 2026. A cash buyer paying up for the cleanest listed pure-play validates the trough.\n- Operating leverage is returning: Q1 2026 (2026-05-07) adjusted EPS $2.10 beat $1.62 by ~30%, with the GAAP loss narrowing to -$0.84 from -$7.78 year-over-year as cost-out drops through on stabilizing volumes.\n- Mix-shift with a margin hook: AMN Language Services acquired Jaide Health on 2026-06-09, an AI-enabled medical interpretation platform, bolting a higher-margin, recurring, less-cyclical line onto a business the market still prices as pure staffing.\n- Price structure held into late July: a fresh 52-week high $36.27, shares above the 50- and 200-day, and the recovery break of the May shelf still intact.\n\n## Bear Case\n- The top line has not turned: the Q2 2026 guide of $620–635M sits below the $634.9M consensus (2026-05-07), with gross margin guided 28–28.5% and adjusted EBITDA margin 6.7–7.2%. The EPS beat is cost-driven; demand-led revenue has not reached guidance.\n- Price outran the broad Street: at ~$32.89 the stock trades above nearly every target except Truist's fresh $40, and the consensus rating stays Hold (~9–13 analysts, median ~$23–30 depending on the aggregator). One outlier does not confirm a re-rating.\n- The easy money is behind it: ~+120% off $14.87 to $36.27 means a fresh buyer funds a leg that already re-rated; cyclical-recovery names hand back the last 30% fast when the weekly demand series hiccups.\n- The peer signal is going dark: CCRN's take-private removes the cleanest listed pure-play read, leaving the Jefferies weekly temp-staffing series as the main high-frequency demand gauge — thinner confirmation than a live listed comp.\n- The binary is 11 days out: the 2026-08-06 print (Q2 results plus the Q3 outlook) is the real test, and a Q3 guide that fails to lift the ~$630M run-rate strands the stock above targets.\n- Still GAAP-lossmaking: trailing net income -$32.44M, EPS -$0.84, no trailing P/E; the forward P/E near 39x already discounts the recovery.\n\n## Setup & Price Structure\n- Last ~$32.89 (2026-07-24), ~9% below the 52-week high $36.27, up roughly +120% off the $14.87 52-week low; market cap ~$1.28B.\n- The fresh highs printed around the 2026-07-22 Truist upgrade; beneath price, the rising 50-day sits in the low-$30s and the May breakout shelf near $26 is the deeper structural line.\n- Above every analyst target except Truist's $40 — extension into overhead supply rather than a clean base.\n- This is a late-stage entry: paying up at the highs into a binary print, with a below-consensus guide already on the table, is stretched. A pullback that holds the $28–30 zone on light volume, or a volume-backed reclaim of a post-print gap, would be the cleaner re-entry; a fresh chase at ~$33 into 2026-08-06 is a pass.\n\n## Catalyst Calendar (next 30 days)\n\n- Weekly (ongoing): Jefferies temp-nursing demand series, the main high-frequency sector read now that CCRN is going private; last flagged +3.6% week-over-week (early June 2026). Three-plus consecutive negative weeks would undercut the bull.\n- ~Q3 2026 (est.): CCRN / Knox Lane take-private close (~$437M) — removes a listed comp from the group.\n- No other dated company catalyst inside the 30-day window.\n\n## Elapsed catalysts\n\n- 2026-08-06 (confirmed): Q2 2026 earnings release ~4:15pm ET, call 5:00pm ET. Q2 revenue guided $620–635M vs $634.9M consensus; the Q3 outlook is the swing factor. Binary — avoid fresh entries into the print. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $28 breaks the July higher-low base and the rising trend carrying the recovery leg; a close beneath the $26 May breakout shelf resets the chart to a failed-recovery value trap.\n- The 2026-08-06 print guiding Q3 revenue under the ~$630M run-rate, or gross margin slipping below the 28% floor — that confirms the top-line stall the guide hints at.\n- Jefferies temp-nursing demand turning negative three-plus straight weeks reverses the demand inflection that underwrites the whole leg.\n- Bull-side confirmation instead: a second and third target following Truist above $34–35 plus a Q3 guide that lifts the run-rate would flip the read from MATURING back toward accelerating and justify paying up for strength.\n\n## Correlation Notes\n- Cleanest peer CCRN (Cross Country Healthcare) is going private (Knox Lane, $13.25/share); its Q1 Travel Nurse & Allied +7% sequential (2026-05-07) is the last clean listed comp, and after close the pure-play sector read thins out.\n- Sector reference points: hospital-system operators (HCA, THC, UHS) and their labor-cost commentary, plus locum and allied-staffing peers.\n- The driver is hospital labor budgets and travel-nurse bill rates; the \"managed care\" theme tag is a mislabel, and the Jefferies weekly temp-staffing demand series is the cleanest gauge of the thesis.\n- Idiosyncratic labor-cycle and print-driven — low correlation to AI/semis leadership despite the Jaide Health AI-interpretation bolt-on, and not an index/macro proxy.",
  "first_seen": "2026-05-10",
  "last_analyzed": "2026-07-26T11:42:17+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}